The new and expanded Second Edition of Pharmaceutical and Medical Device Law: Regulation of Research, Development, and Marketing, offers readers a comprehensive and readable text about the dynamic and complex area of pharmaceutical and medical device law in a changing health care landscape, and more.
EXAMINES THE COMPLEX RELATIONSHIPS between the pharmaceutical industry and health care delivery systems, insurers, and regulators.
The new and expanded Second Edition of Pharmaceutical and Medical Device Law: Regulation of Research, Development, and Marketing, offers readers a comprehensive and readable text about the dynamic and complex area of pharmaceutical and medical device law in a changing health care landscape. In this unique treatise, expert authors analyze and organize legal developments affecting the expansive regulatory arena covering drug creation, production, and sales.
With the graying of the Baby Boomer generation and the financial pressures that this group’s increased health care needs have made on federal and state governments, more and more attention is directed to drug costs and the profits of pharmaceutical manufacturers. The federal government’s increased reimbursement for pharmaceutical products under Medicare Part D has created a corresponding pressure on regulators and prosecutors to ensure that providers and pharmaceutical entities do not violate any of a number of applicable statutes and agency regulations. Obtaining a solid understanding about this area of health care practice is critical for transactional attorneys, for lawyers who counsel clients about compliance considerations, and for litigators who get involved in some of these complex cases. Annual supplements to the treatise will be invaluable in tracking changes to the relevant laws and how they are interpreted by the government and the courts.
Highlights in Pharmaceutical and Medical Device Law: Regulation of Research, Development, and Marketing, Second Edition include brand-new chapters on:
The Second Edition also provides:
The 2016 Supplement includes:
the U.S. Supreme Court's decision in Escobar, and the implied certification theory of liability under the False Claims Act
a new section on the FDA's draft guidance on compounding prescription requirements for traditional compounding pharmacies, those within a hospital, and standalone pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act
FDA settlements with Amarin Pharmaceuticals and Pacira Pharmaceuticals indicating an evolution in the FDA’s attitude towards off-label promotion
recent HIPAA settlements, as well as developments in HIPAA enforcement, including the OIG’s call for stronger oversight by the OCR of HIPAA’s Privacy Rule and breach enforcement efforts
guidance from the FDA on the Zika virus and managing blood supply risks
significant updates on biologic and biosimilar products law, including Inflectra, the FDA’s second approved biosimilar, and new sections on biosimilar naming and labeling
proposed revisions to the Common Rule regulations for protection of human subjects in research, published by HHS and fifteen other federal departments and agencies
a new section on the OIG’s safe harbor under the Anti-Kickback Statute for electronic prescribing under Medicare Part D
antitrust caselaw updates on schemes to delay marketing of generics, as well as a decision on the relationship between ANDA filings and the minimum-contacts requirement for personal jurisdiction in two generics cases
other settlements with the federal government, including the $784.6 million Wyeth and Pfizer settlement under the False Claims Act, as well as the $646 million settlement with Olympus Corporation of the Americas, Inc. (OCA) which combined violations of the Anti-Kickback Statute, the False Claims Act, and the Foreign Corrupt Practices Act
litigation on securities law issues such as scienter, predictions of drug approvals, statements during IPOs, and the importance of loss causation
the FDA’s March 2016 update of its Manual of Policies and Procedures 5240.3, now containing a new category of expedited “sole-source” Abbreviated New Drug Applications (ANDA) submissions
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)